Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis
Open Access
- 21 May 2025
- journal article
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2505090
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by scarring and tissue remodeling. Current treatments have limited efficacy and significant side effects. To address these limitations, we developed AD-214, an anti-CXCR4-Fc-fusion protein composed of an anti-CXCR4 i-body (AD-114) tethered at its C terminus to constant domains 2 and 3 of the Fc region of a mutated human IgG1 lacking effector function. AD-214 binds with high affinity and specificity to CXCR4, modulates intracellular signaling, and inhibits key fibrotic pathways. Using fibrosis models, we demonstrate that AD-214 treatment significantly reduces collagen deposition and lung remodeling and has a unique mode of action. In Phase 1 clinical trials, intravenous infusion of AD-214 led to high and sustained CXCR4 receptor occupancy (RO), but whether RO and efficacy are causally linked remained to be determined. Herein, we demonstrate that CXCR4 RO by AD-214 inhibits primary human leukocyte migration, a model fibrotic process, and that migration inhibition is achievable at concentrations of AD-214 present in the serum of healthy human volunteers administered AD-214. Taken together, these data provide proof of concept for AD-214 as a novel treatment strategy for IPF and suggest that clinically feasible dosing regimens may be efficacious.Keywords
Funding Information
- AdAlta Ltd
This publication has 59 references indexed in Scilit:
- CXCR4 signaling in the regulation of stem cell migration and developmentJournal of Neuroimmunology, 2008
- Important Roles for Macrophage Colony-stimulating Factor, CC Chemokine Ligand 2, and Mononuclear Phagocytes in the Pathogenesis of Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Dual Effect of AMD3100, a CXCR4 Antagonist, on Bleomycin-Induced Lung InflammationThe Journal of Immunology, 2007
- Rapid Structure-Activity and Selectivity Analysis of Kinase Inhibitors by BioMAP Analysis in Complex Human Primary Cell-Based ModelsASSAY and Drug Development Technologies, 2004
- Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosisJournal of Clinical Investigation, 2004
- An integrative biology approach for analysis of drug action in models of human vascular inflammationThe FASEB Journal, 2004
- CXCR4–SDF-1 Signalling, Locomotion, Chemotaxis and AdhesionJournal of Molecular Histology, 2004
- The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1Nature, 1996
- The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entryNature, 1996
- Simple method of estimating severity of pulmonary fibrosis on a numerical scale.Journal of Clinical Pathology, 1988